List view / Grid view
11 May 2015 | By Victoria White
Data from a post-hoc analysis of a Phase 3a trial demonstrates the weight-loss-dependent and independent effects of liraglutide 3 mg...
11 May 2015 | By Victoria White
SMC has accepted seven new medicines for use in NHS Scotland. Two of these medicines, Azerra and Zydelig, were considered under SMC’s PACE process...
11 May 2015 | By Victoria White
Boyds has joined CTD Holdings’ Clinical Programme Team along with Aptus Clinical and KJC Statistics to develop orphan drug Trappsol Cyclo with Accenture...
11 May 2015 | By Victoria White
The FDA has approved Avelox in the US to treat patients with plague, including pneumonic plague and septicemic plague...
11 May 2015 | By Victoria White
Transition Therapeutics has exclusively licensed worldwide rights to a novel small molecule drug candidate, TT701, from Eli Lilly and Company...
11 May 2015 | By Victoria White
WHO has declared Liberia free of Ebola transmission - forty-two days have passed since the last laboratory-confirmed case was buried...
11 May 2015 | By Victoria White
Roche has announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2015).
8 May 2015 | By Victoria White
WHO has called on scientists, national authorities and the media to follow best practices for disease names to minimise unnecessary negative effects...
8 May 2015 | By
The FDA has lifted the clinical hold on clinical studies of ND0612H and ND0612L, NeuroDerm's product candidates for the treatment of Parkinson’s disease...
8 May 2015 | By Victoria White
The FDA has granted Fast Track Designation for cobiprostone, a locally acting chloride channel activator, for the prevention of oral mucositis.
8 May 2015 | By Victoria White
Eleven Biotherapeutics presented clinical data for EBI-005 for dry eye disease and allergic conjunctivitis at the ARVO 2015 Annual Meeting...
8 May 2015 | By Victoria White
The European Commission has approved Novartis’ Zykadia to treat adult patients with ALK+ NSCLC previously treated with crizotinib...
8 May 2015 | By Victoria White
The Asia-Pacific treatment market for psoriasis will almost double in value, from $690 million in 2014 to $1.2 billion by 2021, representing a CAGR of 8.4%...
7 May 2015 | By Victoria White
Ohr Pharmaceutical presented the results from the Phase II IMPACT study evaluating OHR-102 combination therapy for the treatment of the wet-AMD at ARVO...
7 May 2015 | By kdm communications
Operating capacity set to more than double in response to rising demand...
